Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and Safety of Adalimumab Biosimilar GP2017 in Patients with Inflammatory Bowel Disease
Marta Vernero, Cristina Bezzio, Davide Giuseppe Ribaldone, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 21, pp. 6839-6839
Open Access | Times Cited: 10

Showing 10 citing articles:

Biosimilars versus biological therapy in inflammatory bowel disease: challenges and targeting strategies using drug delivery systems
Ahmed Aljabri, Ghareb M. Soliman, Yasmin N. Ramadan, et al.
Clinical and Experimental Medicine (2025) Vol. 25, Iss. 1
Open Access | Times Cited: 1
Additional Data in Expanded Patient Populations and New Indications Support the Practice of Biosimilar-to-Biosimilar Switching
Hillel P. Cohen, Wolfram Bodenmueller
BioDrugs (2024) Vol. 38, Iss. 3, pp. 331-339
Open Access | Times Cited: 7
Anti-TNFα in inflammatory bowel disease: from originators to biosimilars
Zhen Zeng, Hao Lin, Mingshan Jiang, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 4
Biobetters and biosimilars in Inflammatory Bowel Disease
Jacopo Fanizza, Ilaria Faggiani, Mariangela Allocca, et al.
Best Practice & Research Clinical Gastroenterology (2025), pp. 101992-101992
Closed Access
Switching from Adalimumab Reference Product to and Among Adalimumab Biosimilars Outside the USA: Insights for US Clinicians
John Tesser, Aline Charabaty, Adelaide A. Hebert
BioDrugs (2025)
Open Access
Efficacy, Safety and Persistence on Therapy after Non-medical Switching from Originator Adalimumab in IBD-Real Life Experience from Two Tertiary Centres
Popescu Remus, Teodora SPATARU, Monica State, et al.
(2024)
Open Access | Times Cited: 1
The Efficacy, Safety, and Persistence of Therapy after Non-Medical Switching from an Originator Adalimumab in Inflammatory Bowel Disease: Real-Life Experience from Two Tertiary Centres
Teodora SPATARU, Remus Popescu, Monica State, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 10, pp. 1319-1319
Open Access | Times Cited: 1
Therapeutic Effects of Adalimumab Biosimilars on Rheumatoid Arthritis
Delan Wang
MedScien (2024) Vol. 1, Iss. 7
Open Access
Biologics in Focus: A Comprehensive Review of Current Biological and Small Molecules Therapies for Crohn’s Disease in the United Arab Emirates (UAE)
Laith Alrubaiy, Louise Christine Pitsillides, T O'Connor, et al.
Gastrointestinal Disorders (2024) Vol. 6, Iss. 3, pp. 644-660
Open Access
Clinical experience of using biosimilars in Crohn’s disease and their effectiveness
Léa Sequier, Bénédicte Caron, Silvio Danese, et al.
Expert Opinion on Biological Therapy (2024), pp. 1-25
Closed Access
Page 1

Scroll to top